Altogether, a large body of evidence demonstrates that the NLRP3 inflammasome contributes significantly to the development and progression of obesity-associated comorbidities such as IR, T2DM, atherosclerosis and NAFLD. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatotic liver disease.